Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703124 | 0.81 | HTT (0.44) | CYP2D6HTTALDH1A1GRM2 | |
| SCHEMBL6823635 | 0.81 | LMNA (0.46) | CYP2D6HTTALDH1A1GRM2 | |
| SCHEMBL4612812 | 0.79 | NR1H2 (0.39) | MLYCDHTTALDH1A1 | |
| SCHEMBL29225360 | 0.77 | LMNA (0.40) | HTTALDH1A1 | |
| SCHEMBL3996429 | 0.77 | NR1H2 (0.41) | ALDH1A1 | |
| SCHEMBL8888411 | 0.73 | RAB9A (0.51) | HTT | |
| SCHEMBL28740014 | 0.72 | CNR2 (0.40) | CYP2D6HTTALDH1A1 | |
| SCHEMBL28715744 | 0.71 | LMNA (0.46) | ALDH1A1GRM2 | |
| SCHEMBL28740084 | 0.71 | MAPT (0.43) | ACHECYP2D6ALDH1A1 | |
| SCHEMBL29020286 | 0.71 | NPC1 (0.48) | ELANEALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476423-B1 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | AMGEN INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-7326812-B2 | Lipid diseases; metabolism diosrders; antiproliferative agents | AMGEN INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7071358-B2 | Arylsulfonamidobenzylic compounds | AMGEN INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1476423-A4 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1476423-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | Tularik Inc. (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | TULARIK INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003063576-A2 | ARYLSULFONAMIDOBENZYLIC COMPOUNDS | TULARIK INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122239-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MLYCD 488/4885ELANE 1433/4885ACHE 4788/4885 |
| US-20030229093-A1 | Arylsulfonamidobenzylic compounds | FASN, ARSA, HSD17B4 | MLYCD 488/4885ELANE 1433/4885ACHE 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.